美国医疗保险早期阿尔茨海默病患者使用Lecanemab的预算影响：亚组分析

数据集获取（Figshare）

• 源站标题：Budget impact of lecanemab for medicare beneficiaries with early Alzheimer’s disease in the United States: a subgroup analysis
• DOI：10.6084/m9.figshare.29085826.v1
• 发布日期：2025-05-16
• 文件数：2 个
• 文件总体积：495.80 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Budget_impact_of_lecanemab_for_medicare_beneficiaries_with_early_Alzheimer_s_disease_in_the_United_States_a_subgroup_analysis/29085826

命令行下载

curl -L -o "ierp_a_2507427_sm2741.docx" "https://ndownloader.figshare.com/files/54592327"
curl -L -o "ierp_a_2507427_sm2740.docx" "https://ndownloader.figshare.com/files/54592330"

文件清单

• ierp_a_2507427_sm2741.docx（96.00 KB）
• ierp_a_2507427_sm2740.docx（399.80 KB）

文件总体积 495.80 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

In 2024, Alzheimer’s disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibodies. With an economic burden surpassing $345 billion, $222 billion borne by Medicare and Medicaid, this study evaluates lecanemab’s budgetary impact for early AD, including subgroup analyses by gender and race.
A budget impact model evaluated LECA for early Alzheimer’s disease, comparing scenarios with and without the therapy. Inputs included market share, costs, duration, and compliance. Gender and race subgroup analyses, annual costs, PMPM, PTMPM, and sensitivity analysis outcomes were assessed to explore parameter-driven variability comprehensively.
Introducing LECA for over 3.5 million eligible early AD patients in the U.S. may generate a three-year budget impact of $4.1 billion for Medicare. Incremental PMPM savings were $1.4, and PTMPM savings reached $24.1. Subgroup analyses revealed no significant gender or racial differences in PMPM and PTMPM, with variability only in overall budget impact. Sensitivity analyses indicate that enhanced healthcare resource utilization, reduced disease severity, and improved cost-efficiency among males contribute to strengthening Medicare’s budget sustainability.
Utilizing LECA as a treatment for early AD is expected to be cost saving with respect to Medicare budgets in the U.S.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.29085826.v1（source: https://tandf.figshare.com/articles/dataset/Budget_impact_of_lecanemab_for_medicare_beneficiaries_with_early_Alzheimer_s_disease_in_the_United_States_a_subgroup_analysis/29085826）。